Details of the Drug Combinations

General Information of This Drug (ID: DMHZCPO)

• Drug Name: Ibrutinib (DMHZCPO)
• Synonyms: PCI-32765; Ibrutinib (BTK inhibitor)

Indication

Mantle cell lymphoma; ICD 11: 2A85.5; Status: Approved [1]; Small lymphocytic lymphoma; ICD 11: 2A82.0; Status: Approved [2]; Waldenstrom macroglobulinemia; ICD 11: 2A85.4; Status: Approved [2]; B-cell non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Phase 3 [3]; Diffuse large B-cell lymphoma; ICD 11: 2A81; Status: Phase 3 [3]; Follicular lymphoma; ICD 11: 2A80; Status: Phase 3 [3]; Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Phase 3 [3]; Pancreatic cancer; ICD 11: 2C10; Status: Phase 3 [3]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 2 [4]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

58 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Alacepril + Ibrutinib	DCI1AZT	Alacepril	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Alpelisib + Ibrutinib	DC9T5MF	Alpelisib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
AR-42 + Ibrutinib	DCD8YVA	AR-42	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Azacitidine + Ibrutinib	DCBJT6J	Azacitidine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Bardoxolone methyl + Ibrutinib	DCUZKN5	Bardoxolone methyl	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
BMS-509744 + Ibrutinib	DCW6I4D	BMS-509744	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Bortezomib + Ibrutinib	DCP3W8D	Bortezomib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
BX-795 + Ibrutinib	DC8Q8M8	BX-795	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
CUDC-101 + Ibrutinib	DCPQDCM	CUDC-101	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Cytarabine + Ibrutinib	DC5RJ7J	Cytarabine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Dasatinib + Ibrutinib	DC8PXRI	Dasatinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Deguelin + Ibrutinib	DCR7FY1	Deguelin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Docetaxel + Ibrutinib	DCDM5FX	Docetaxel	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Doxorubicin + Ibrutinib	DC5VD8M	Doxorubicin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Elesclomol + Ibrutinib	DCHTMDS	Elesclomol	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Etoposide + Ibrutinib	DCRC0LT	Etoposide	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Everolimus + Ibrutinib	DCB8YYZ	Everolimus	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Flavopiridol + Ibrutinib	DCEC7I3	Flavopiridol	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Gemcitabine + Ibrutinib	DCY768L	Gemcitabine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
GYKI-53655 + Ibrutinib	DCXWG4D	GYKI-53655	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Ibrutinib + Panobinostat	DCT18ZC	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Ibrutinib + Idarubicin	DCEOQ9S	Idarubicin	Glioblastoma? (Cell Line: T98G)	[5]
Ibrutinib + PF-562271	DCXE3QG	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Ibrutinib + Ibrutinib	DCP3507	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
IC87114 + Ibrutinib	DCPSJ80	IC87114	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Idelalisib + Ibrutinib	DC86FWO	Idelalisib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
KU-0060648 + Ibrutinib	DC61O2N	KU-0060648	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Lenalidomide + Ibrutinib	DC631RU	Lenalidomide	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Meclinertant + Ibrutinib	DCL3POV	Meclinertant	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Methotrexate + Ibrutinib	DCAU7HL	Methotrexate	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Midostaurin + Ibrutinib	DCZHSVE	Midostaurin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Mitomycin + Ibrutinib	DC5RB6N	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
MK-2206 + Ibrutinib	DCKXOGA	MK-2206	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Nintedanib + Ibrutinib	DC3796J	Nintedanib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Omeprazole + Ibrutinib	DCGAYZN	Omeprazole	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
OSI-027 + Ibrutinib	DC72HKZ	OSI-027	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PD-0325901 + Ibrutinib	DCWFXV9	PD-0325901	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Perifosine + Ibrutinib	DCK5F42	Perifosine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PF-03772304 + Ibrutinib	DCSYR2F	PF-03772304	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PF-228 + Ibrutinib	DCVW570	PF-228	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PF-562271 + Ibrutinib	DCEJGF7	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PHA-690509 + Ibrutinib	DCUAESG	PHA-690509	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PHA-793887 + Ibrutinib	DCCJ2JV	PHA-793887	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PI-103 + Ibrutinib	DCBZSSC	PI-103	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PLX-4720 + Ibrutinib	DCLZP62	PLX-4720	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
PMID28460551-Compound-2 + Ibrutinib	DCUSTLK	PMID28460551-Compound-2	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Pralatrexate + Ibrutinib	DCKHWMU	Pralatrexate	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Pyrimethamine + Ibrutinib	DCVQFAN	Pyrimethamine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Raltitrexed + Ibrutinib	DCYPFCW	Raltitrexed	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
RTB101 + Ibrutinib	DCBDYYO	RTB101	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Sirolimus + Ibrutinib	DCC6ERM	Sirolimus	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Taxol + Ibrutinib	DC2O7Y9	Taxol	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Topetecan + Ibrutinib	DCXXLHC	Topetecan	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Trifluridine + Ibrutinib	DCE1YBQ	Trifluridine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Trimetrexate + Ibrutinib	DCJMY69	Trimetrexate	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Vincristine + Ibrutinib	DCEKV5U	Vincristine	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Vorinostat + Ibrutinib	DCGA4T4	Vorinostat	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
Zarnestra + Ibrutinib	DCFS3BY	Zarnestra	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]

23 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Abexinostat + Ibrutinib	DCU9N9T	Abexinostat	Diffuse Large B-cell Lymphoma	[6]
Azd2014 + Ibrutinib	DCTN1JU	Azd2014	Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma	[7]
Bay 80-6946 + Ibrutinib	DCGSZY3	Bay 80-6946	Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)	[8]
Bortezomib + Ibrutinib	DCZ3JDZ	Bortezomib	Mantle Cell Lymphoma	[9]
Buparlisib + Ibrutinib	DCC1EFA	Buparlisib	Lymphoma	[10]
Carfilzomib + Ibrutinib	DCPX255	Carfilzomib	Lymphoma	[11]
Dexamethasone + Ibrutinib	DCGPVYT	Dexamethasone	Multiple Myeloma	[12]
Docetaxel + Ibrutinib	DCB1H3B	Docetaxel	Metastatic Renal Cell Carcinoma	[13]
Everolimus + Ibrutinib	DCGNDH3	Everolimus	Metastatic Renal Cell Carcinoma	[13]
INCB039110 + Ibrutinib	DCTJ19B	INCB039110	Lymphoma	[14]
Napabucasin + Ibrutinib	DC6U9X7	Napabucasin	Hematologic Malignancy	[15]
Pacritinib + Ibrutinib	DC8F5TL	Pacritinib	Chronic Lymphocytic Leukemia	[16]
Rocilinostat + Ibrutinib	DCAWG8H	Rocilinostat	Recurrent Chronic Lymphoid Leukemia	[17]
Ruxolitinib + Ibrutinib	DCMSI3U	Ruxolitinib	Steroid Refractory GVHD	[18]
Ruxolitinib + Ibrutinib	DCMBQ7F	Ruxolitinib	Leukemia, Lymphocytic, Chronic, B-Cell	[19]
Temozolomide + Ibrutinib	DC0J4MX	Temozolomide	Glioblastoma	[20]
Umbralisib + Ibrutinib	DC05K5A	Umbralisib	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	[21]
Duvelisib + Ibrutinib	DCL16B4	Duvelisib	Small Lymphocytic Leukemia (SLL)	[22]
Fludarabine + Ibrutinib	DCHNM7Y	Fludarabine	Chronic Lymphocytic Leukemia	[23]
Venetoclax + Ibrutinib	DC36D1X	Venetoclax	Mantle Cell Lymphoma	[24]
Acalabrutinib + Ibrutinib	DC9I6MQ	Acalabrutinib	Chronic Lymphocytic Leukemia	[25]
Venetoclax + Ibrutinib	DCOMIIC	Venetoclax	Leukemia, Lymphocytic, Chronic, B-Cell	[26]
Venetoclax + Ibrutinib	DCBV2M1	Venetoclax	Chronic Lymphocytic Leukemia	[27]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912).
• [2] Ibrutinib FDA Label
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT03939182) Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
• [7] ClinicalTrials.gov (NCT02780830) AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• [8] ClinicalTrials.gov (NCT03581942) Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
• [9] ClinicalTrials.gov (NCT02356458) Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
• [10] ClinicalTrials.gov (NCT02756247) A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
• [11] ClinicalTrials.gov (NCT02269085) Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
• [12] ClinicalTrials.gov (NCT01478581) Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
• [13] ClinicalTrials.gov (NCT02599324) Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
• [14] ClinicalTrials.gov (NCT02760485) A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
• [15] ClinicalTrials.gov (NCT02352558) A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
• [16] ClinicalTrials.gov (NCT02677948) Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
• [17] ClinicalTrials.gov (NCT02787369) ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
• [18] ClinicalTrials.gov (NCT05052385) ECP Combination Study
• [19] ClinicalTrials.gov (NCT02912754) Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
• [20] ClinicalTrials.gov (NCT03535350) Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
• [21] ClinicalTrials.gov (NCT02268851) A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
• [22] ClinicalTrials.gov (NCT04209621) Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• [23] ClinicalTrials.gov (NCT02514083) A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
• [24] ClinicalTrials.gov (NCT02471391) ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
• [25] ClinicalTrials.gov (NCT06136559) A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
• [26] ClinicalTrials.gov (NCT03462719) A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• [27] ClinicalTrials.gov (NCT02950051) Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation